A comparison of clinical characteristics and outcomes of patients on extracorporeal membrane oxygenation (ECMO) in COVID-19, influenza and ARDS of other ethiologies
All ARDS patients on extracorporeal membrane oxygenation (ECMO) during January 1st 2016 and January 10th 2022 in University Medical Center Ljubljana were included and their clinical characteristics and outcomes were studied according to ARDS ethiology: COVID-19, influenza and other ethiologies.
Study Type
OBSERVATIONAL
Enrollment
100
180-day survival
180-day survival from ECMO implantation
Time frame: From day of ECMO-implant for every 24 hours until date of death or survival at 180 days
Days on ECMO
Days on ECMO from ECMO implantation
Time frame: From day of ECMO-implant for every 24 hours until date of weaning or death
Weaning from ECMO
Weaning from ECMO
Time frame: From day of ECMO-implant until date of death or weaning
ICU length of stay
ICU length of stay from ECMO implantation
Time frame: From day of ICU-admission for every 24 hours until date of death or date of ICU discharge
ICU survival
ICU survival from ECMO implantation
Time frame: From day of ICU-admission for every 24 hours until date of death or survival at ICU discharge
Hospital survival
Hospital survival from ECMO implantation
Time frame: From day of hospital admission for every 24 hours until date of death or survival at hospital discharge
30-day survival
30-day survival from ECMO implantation
Time frame: From day of ECMO-implant for every 24 hours until date of death or survival at 30 days
90-day survival
90-day survival from ECMO implantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From day of ECMO-implant for every 24 hours until date of death or survival at 90 days